Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd has announced that its Board of Directors will convene on November 2, 2026. The primary agenda item for this meeting is to consider and approve the Un-audited Financial Results for the half-year period ending September 30, 2026. In line with the company's insider trading policy, the trading window for designated persons has been closed since October 1, 2026, and will reopen 48 hours after the financial results are officially declared to the stock exchange.

Ganga Pharmaceuticals Ltd announced the re-appointment of Mr. Bharat Brijmohan Sharma as Managing Director for a further period of three years, effective April 01, 2026. The approval was granted at the company's 37th Annual General Meeting held on September 26, 2026. Mr. Sharma, who has over 35 years of experience in the pharma industry, is not liable to retire by rotation and has not been debarred from holding a director's office by any authority. His spouse, Mrs. Srijna Sharma, is also a Whole-time Director.

Ganga Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons from October 1, 2026. This closure is in preparation for the declaration of the company's un-audited financial results for the half-year ending September 30, 2026. The trading window is expected to reopen 48 hours after the official announcement of these financial results to the stock exchange, adhering to the company's code of conduct for preventing insider trading.

Ganga Pharmaceuticals Ltd has issued letters to shareholders whose email addresses are not registered with the RTA or the company. These letters provide a web link to access the AGM Notice and Annual Report for the financial year ended March 31, 2026, in compliance with SEBI (LODR) Regulations, 2015. The AGM is scheduled for September 26, 2026. Shareholders are urged to register their email IDs for future communications and benefits.

Ganga Pharmaceuticals Ltd has announced the details for its 37th Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM is scheduled to be held on Saturday, September 26, 2026, at 4:30 p.m. at the company's registered office in Palghar. The company has fixed Friday, September 18, 2026, as the cut-off date for determining voting eligibility. Remote e-voting will be available through CSDL from September 23 to September 25, 2026. The Register of Members and Share Transfer Books will be closed from September 20 to September 26, 2026, for the AGM. The integrated Annual Report for FY 2025-26, along with the AGM notice, has been uploaded to the company's website.

Ganga Pharmaceuticals Ltd has announced its 37th Annual General Meeting (AGM) scheduled for Saturday, September 26, 2026, at 4:30 p.m. at its registered office. The company has fixed Friday, September 18, 2026, as the cut-off date for determining voting eligibility. Remote e-voting will be available from September 23 to September 25, 2026. The Annual Report for FY 2025-26 and the AGM notice have been uploaded to the company's website, www.ayurvedganga.com. The register of members and share transfer books will be closed from September 20 to September 26, 2026, for the AGM.

Ganga Pharmaceuticals Ltd has announced its 37th Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, at 4:30 p.m. at its registered office. The company has set Friday, September 18, 2026, as the cut-off date for determining voting eligibility. Remote e-voting will be available from September 23 to September 25, 2026, through CSDL. The Register of Members and Share Transfer Books will be closed from September 20 to September 26, 2026. The Annual Report for FY 2025-26, along with the AGM notice, has been uploaded to the company's website.

Ganga Pharmaceuticals Ltd has appointed M/s. D Maurya & Associates as its Secretarial Auditor for the financial year 2026-27, following the recommendation of the Audit Committee and approval by the Board of Directors on May 21, 2026. The appointment complies with Regulation 30 of the SEBI Listing Regulations. M/s. D Maurya & Associates is a Mumbai-based firm established in 2010, with Dhirendra Maurya as its proprietor.

Ganga Pharmaceuticals Ltd has appointed M/s. Deepak Jedhe & Co, Chartered Accountants, as its Internal Auditor for the financial year 2026-27. The appointment was approved by the Board of Directors on May 21, 2026, based on the recommendation of the Audit Committee. Deepak Jedhe & Co is a Chartered Accountancy firm founded in 2015, offering assurance, taxation, and advisory services.

Ganga Pharmaceuticals Ltd. announced that its Board of Directors approved the audited financial results for the half year and financial year ended March 31, 2026, following a meeting held on May 21, 2026. The statutory auditors have issued an audit report with an unmodified opinion on these results. The financial results and auditor's report are available on the company's website.